Febuxostat Ethyl Ester CAS 160844-75-7 Purity >99.0% (HPLC) Febuxostat Intermediate Factory
Ruifu Chemical Supply Febuxostat Related Intermediates:
Febuxostat CAS 144060-53-7
Ethyl 2-Chloroacetoacetate CAS 609-15-4
4-Hydroxythiobenzamide CAS 25984-63-8
Ethyl 2-(3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3
Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7
Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2
Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5
Chemical Name | Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate |
Synonyms | Febuxostat Ethyl Ester; Febuxostat Ethyl Ester Impurity; Febuxostat Impurity 15; Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate; 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylic Acid Ethyl Ester |
CAS Number | 160844-75-7 |
CAT Number | RF-PI1857 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C18H20N2O3S |
Molecular Weight | 344.43 |
Melting Point | 174.0 to 178.0℃ |
Density | 1.22 |
Brand | Ruifu Chemical |
Item | Specifications |
Appearance | White or Off-White Powder |
Identification | HPLC, NMR; LC-MS |
Related Substances | |
Individual Impurity | <0.50% |
Total Impurities | <1.00% |
Loss on Drying | <0.50% |
Residue on Ignition | <0.20% |
Heavy Metals | <10ppm |
Purity / Analysis Method | >99.0% (HPLC) |
Test Standard | Enterprise Standard |
Usage | Intermediate of Febuxostat (CAS: 144060-53-7) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate (CAS: 160844-75-7) is an intermediate or impurity of Febuxostat (CAS: 144060-53-7), a xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout. 40-120 mg/day Febuxostat was proven effective in lowering serum urate levels when administered to manage hyperuricemia in patients with gout.